Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 20/20 | 0.68 |
| ▸ | CHRM2 | P08172 | 15/20 | 0.68 |
| ▸ | CHRM1 | P11229 | 15/20 | 0.68 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.61 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.61 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2485702 | 0.93 | CHRM3 (0.78) | CHRM3CHRM2CHRM1CHRM5CHRM4 | |
| SCHEMBL17313910 | 0.92 | CHRM3 (0.64) | CHRM3CHRM2CHRM1CHRM5CHRM4 | |
| SCHEMBL19856635 | 0.91 | CHRM3 (0.73) | CHRM3CHRM2CHRM1CHRM5CHRM4 | |
| SCHEMBL17320535 | 0.88 | CHRM3 (0.61) | CHRM3CHRM2CHRM1CHRM5CHRM4 | |
| SCHEMBL15761735 | 0.87 | CHRM3 (0.65) | CHRM3CHRM2CHRM1CHRM5CHRM4 | |
| SCHEMBL17327537 | 0.86 | CHRM2 (0.70) | CHRM3CHRM2CHRM1CHRM5CHRM4 | |
| SCHEMBL19856669 | 0.84 | CHRM3 (0.71) | CHRM3CHRM2CHRM1CHRM5CHRM4 | |
| SCHEMBL15761739 | 0.84 | CHRM3 (0.62) | CHRM3CHRM2CHRM1CHRM5CHRM4 | |
| SCHEMBL15761757 | 0.84 | CHRM3 (0.75) | CHRM3CHRM2CHRM1CHRM5CHRM4 | |
| SCHEMBL19856658 | 0.83 | CHRM2 (0.85) | CHRM3CHRM2CHRM1CHRM5CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3152204-B1 | CARBAMATE DERIVATIVES WHICH ARE BOTH PHOSPHODIESTERASE 4 (PDE4) ENZYME INHIBITORS AND MUSCARINIC M3 RECEPTOR ANTAGONISTS | CHIESI FARM SPA (IT) | 2018-03-28 | — | — | EP | disclosed |
| US-9326976-B2 | Carbamate derivatives | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-05-03 | — | — | US | disclosed |
| US-9326976-B2 | Carbamate derivatives | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-05-03 | — | — | US | disclosed |
| US-20150352090-A1 | CARBAMATE DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-12-10 | — | — | US | disclosed |
| US-20150352090-A1 | CARBAMATE DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-12-10 | — | — | US | disclosed |
| WO-2015185650-A1 | CARBAMATE DERIVATIVES WHICH ARE BOTH PHOSPHODIESTERASE 4 (PDE4) ENZYME INHIBITORS AND MUSCARINIC M3 RECEPTOR ANTAGONISTS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150352090-A1 | CARBAMATE DERIVATIVES | CHRM3, PDE4A, PDE4B | CHRM3 1/4885CHRM2 11/4885CHRM1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.